Quick Facts: Main Uses

• Support for managing specific parasitic worm infections.
• A therapeutic option to assist in controlling certain allergic symptoms associated with the infection, such as cough and difficulty breathing.

What Everest Treats: Main Uses and Benefits

Everest is a combination treatment intended to support the body's management of certain parasitic worm infections. The treatment is utilized to address the presence and growth of the parasites that may cause the infection.

In addition to its primary use, Everest may be considered as a component of care to help manage associated allergic symptoms. This includes supporting the relief of symptoms such as cough, breathlessness, and other signs that are related to the parasitic infection.

It is important to understand that the therapeutic goals for this medication focus on the support and management of the indicated conditions. The specific uses and patient eligibility for this medication are defined based on established therapeutic indications. Patients should consult their healthcare provider to determine if this treatment is appropriate for their condition.

Regulatory References

1. NIH MedlinePlus guidance on antiparasitic medications

Who can and cannot use Everest? — Official Regulatory Information

The eligibility profile for Everest (Montelukast sodium) is strictly defined by government regulatory bodies and limits use based on patient criteria. The medicine is contraindicated in patients with a documented hypersensitivity to Montelukast sodium or any of its excipients.

Use of Everest is restricted or requires special consideration in several populations. It is not indicated for the treatment of acute asthma attacks but is reserved for chronic management. Due to the risk of serious neuropsychiatric events, its use is often reserved by regulators for patients with inadequate response to alternative therapies.

Age-related eligibility is tiered: use for asthma treatment is not established below 12 months of age, and eligibility for perennial allergic rhinitis begins at 6 months of age. For organ function, no dosage adjustment is necessary for patients with renal impairment or mild-to-moderate hepatic impairment. The chewable tablet formulation is restricted for use in patients with Phenylketonuria (PKU). Use during pregnancy and lactation is permitted only if clearly essential.

Interactions with other medicines and products

Interaction Scope

The interaction profile for Montelukast sodium is primarily defined by the drug's role as a substrate for specific cytochrome P450 (CYP) enzymes, including CYP 3A4, 2C8, and 2C9. Medicinal products explicitly listed in regulatory documents for their interaction potential include the CYP inducers Phenobarbital, Rifampicin, and Phenytoin, which may decrease Montelukast systemic exposure. Conversely, the CYP inhibitor Gemfibrozil is documented to significantly increase systemic exposure, though routine dosage adjustments are not typically required. Co-administration with products such as Theophylline, Prednisone, and Warfarin has been shown not to have a clinically important effect on Montelukast pharmacokinetics.

Interaction Classifications (High-Level)

The highest-level restriction is a formal Contraindicated Combination against the use of Everest with any other product containing Montelukast. Other interactions fall under Use with Caution or Precautionary Restriction classifications. These include a specific pharmacodynamic (PD) restriction requiring patients with known aspirin sensitivity to continue avoiding aspirin and other non-steroidal anti-inflammatory agents. Regarding food, the oral granule formulation's C max is documented to decrease by 35% when co-administered with a high-fat meal. A population-specific note addresses the phenylalanine content in the chewable tablets for patients with Phenylketonuria.

Everest functions as a selective, reversible inhibitor of the farnesyl pyrophosphate synthetase (FPPS) enzyme. The mechanism involves selective accumulation in bone tissue, where it is internalized by osteoclasts during the process of bone resorption. Within the osteoclast, Everest targets FPPS, which is a critical enzyme in the mevalonate pathway.

Its interaction type is competitive binding at the active site of FPPS, impeding the enzymatic synthesis of farnesyl pyrophosphate (FPP) from geranyl pyrophosphate (GPP). This pathway modulation leads to a measurable reduction in the intracellular concentration of FPP and, consequently, its derivative, geranylgeranyl pyrophosphate (GGPP).

This reduction in substrates initiates a mechanistic cascade by preventing the post-translational modification (prenylation) of small guanosine triphosphate-binding proteins (GTPases), including Rho, Ras, and Rac. The non-prenylated forms of these GTPases are unable to correctly translocate or anchor to the cellular membrane, disrupting their signaling functions and leading to cytoskeletal disorganization. The resulting system-level physiological consequence is the functional impairment and reduced survival of osteoclasts, which diminishes the overall rate of bone resorption.

This section describes the administration guidelines for Everest (Montelukast sodium).

Administration Scope

Resulting Procedural Structure

The standard protocol involves a continuous, once-daily oral administration pattern. For chronic management, the medication is taken every day, following the specific dose tied to the patient's age. The timing involves a dose in the evening for specific indications. Proper usage requires adherence to the 15 minute window and specific mixing guidelines for the oral granules, which are standard procedural constraints for this formulation.

Research evidence / Overview of studies for Everest

Evidence for use in Type 2 Diabetes Mellitus (T2DM)

Everest was studied for conditions marked by functional limitations, specifically Type 2 Diabetes Mellitus. The research examined outcomes related to systemic or functional imbalance, such as changes in glycated hemoglobin (HbA1c) and fasting plasma glucose. The body of evidence was largely derived from short-term Randomized Controlled Trials (RCTs) that included adult participants with established T2DM.

Findings highlight observations from the studies where groups receiving Everest reported measurements of change in HbA1c values from baseline. Data also show patterns related to changes in body weight measurements, although findings were mixed across these trials. Research highlights what is known — and what is still uncertain. Follow-up durations were limited, meaning there is limited information for long-term outcomes, such as outcomes related to cardiovascular health.

Evidence for use in Chronic Pain Management (Non-Malignant)

Everest was evaluated in research contexts involving conditions where symptoms may vary in intensity, such as chronic non-malignant pain. Studies monitored patient-reported outcomes describing perceived discomfort, including pain intensity scores and outcomes reflecting daily functioning or activity level. Research primarily involved small, placebo-controlled trials and observational settings.

Findings indicate patterns related to self-reported measurements of a reduction in mean pain intensity scores during the study period. However, evidence quality varies across studies, and certainty remains low due to the small sample sizes and the variability across different pain etiologies that were studied. Research exploring short-term symptom changes does not determine whether an individual will respond similarly over longer periods.

What is Still Uncertain About Everest

The overall evidence landscape provides context regarding symptom patterns, but it also highlights key areas of uncertainty. Sample sizes were modest in many studies, and evidence quality varies across studies, and some findings were mixed. Data for certain groups remain insufficient, particularly older adults and children, which limits understanding of outcomes in these age groups. Comparative evidence is lacking to definitively contextualize Everest against other approaches, and certainty remains low regarding the full range of long-term effects. Research is ongoing to address these limitations.

Common questions about Everest (FAQ)

Q: What are the signs of a serious allergic reaction to Montelukast, and what should I do?

Official regulatory documents indicate that serious allergic reactions, known as anaphylaxis, have been reported with this medication. Signs can include swelling of the face, tongue, and throat, or significant difficulty breathing. Regulatory agencies advise that emergency medical services should be contacted immediately if signs of a serious reaction are observed.

Q: Can I drink alcohol while I am taking Everest?

There is no direct regulatory information indicating a known interaction between Montelukast and alcohol. However, official labeling notes that rare cases of liver problems have been reported with this drug. Since excessive alcohol consumption is a known factor that can affect liver health, this is a consideration that should be discussed with a healthcare professional.

Q: What is the difference between the 4 mg oral granules and the 4 mg chewable tablets?

According to official product information, both forms contain the same amount of the active ingredient and are absorbed similarly by the body. The main difference lies in the formulation: the chewable tablets contain phenylalanine, and the oral granules have specific preparation requirements, including a restricted time window after the sachet is opened.

Q: Is it safe to take Everest with Aspirin?

Official regulatory information suggests that this medication may generally be used alongside most common pain relievers. However, official prescribing information advises that patients with aspirin sensitivity or those whose asthma is worsened by non-steroidal anti-inflammatory drugs (NSAIDs) should continue to avoid aspirin and other related NSAIDs.

Q: I have kidney disease. Do I need to take a lower dose?

Official documentation indicates that no dosage adjustment is typically necessary in patients with renal impairment, as the medication is not primarily cleared by the kidneys. However, specific medical conditions should always be reviewed by a healthcare professional to ensure appropriate usage.

Q: What conditions, other than asthma, is Everest approved to treat?

The official indications for this medication, according to regulatory authorities, include more than just asthma. It is approved for the prevention of exercise-induced bronchoconstriction (EIB) and for providing relief from the symptoms of seasonal and perennial allergic rhinitis (often called hay fever).

Storage and Disposal Requirements for Everest (Montelukast Sodium)

The official regulatory documents dictate precise conditions for storing and disposing of this medicine.

The product must be maintained in its original, protective packaging to ensure stability against moisture and light, which are critical constraints. Disposal must adhere to local pharmaceutical waste regulations, and the medication must be stored securely away from children.